MedTrace Logo

Safety and Tolerability of EO2002

NCT05587205 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-12-08

No results posted yet for this study

Summary

The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.

Conditions

  • Cataract
  • Endothelial Cell Loss, Corneal

Interventions

BIOLOGICAL

EO2002

Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery

OTHER

Sham injection

Sham injection

Sponsors & Collaborators

  • Emmecell

    collaborator INDUSTRY

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Valeria Sanchez Huerta, MD · Asociacion para Evitar la Ceguera

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-30
Primary Completion
2026-10-06
Completion
2026-10-06
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05587205 on ClinicalTrials.gov